United States - English - NLM (National Library of Medicine)

sandoz inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii - ascorbic acid 80 mg in 4 ml - infuvite pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite pediatric is contraindicated in patients who have: infuvite pediatric has not been studied in pregnant women. pregnant women should follow the u.s. recommended daily allowances for pregnancy because their vitamin requirements may exceed those of non-pregnant women. animal reproduction studies have not been conducted with infuvite pediatric (multiple vitamins injection). infuvite pediatric has not been studied in nursing mothers. lactating women may have vitamin requirements that exceed those of non-lactating women. caution should be exercised when infuvite pediatric is administered to nursing mothers. infuvite pediatric is approved for the prevention of vitamin deficiency in pediatric patients up to 11 years

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) - glycerin 1.2 g - laxative • relieves occasional constipation (irregularity) • generally produces bowel movement in 1⁄4 to 1 hour

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - bacitracin 500 [usp'u] in 1 g - polycin® ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. polycin® ophthalmic ointment is contraindicated in individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - miconazole nitrate (unii: vw4h1cyw1k) (miconazole - unii:7nno0d7s5m), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), petrolatum (unii: 4t6h12bn9u) (petrolatum - unii:4t6h12bn9u) - vusion ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. a positive fungal culture for candida albicans is not adequate evidence of candidal infection since colonization with c. albicans can result in a positive culture. the presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. vusion should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. vusion should not be used as a substitute for frequent diaper changes. the safety and efficacy of vusion have not been demonstrated in immunocompromised patients, or in infants less than 4 weeks of age (premature or term). the safety and efficacy of vusion have not been evaluated in incontinent adult

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - miconazole nitrate (unii: vw4h1cyw1k) (miconazole - unii:7nno0d7s5m), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), petrolatum (unii: 4t6h12bn9u) (petrolatum - unii:4t6h12bn9u) - miconazole nitrate, zinc oxide and white petrolatum ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. a positive fungal culture for candida albicans is not adequate evidence of candidal infection since colonization with c. albicans can result in a positive culture. the presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. miconazole nitrate, zinc oxide and white petrolatum ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. miconazole nitrate, zinc oxide and white petrolatum ointment should not be used as a substitute for frequent diaper changes. the safety and efficacy of miconazole nitrate, zinc oxide and white petrolatum

United States - English - NLM (National Library of Medicine)

sandoz inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii - infuvite pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite pediatric is contraindicated in patients who have: infuvite pediatric has not been studied in pregnant women. pregnant women should follow the u.s. recommended daily allowances for pregnancy because their vitamin requirements may exceed those of non-pregnant women. animal reproduction studies have not been conducted with infuvite pediatric (multiple vitamins injection). infuvite pediatric has not been studied in nursing mothers. lactating women may have vitamin requirements that exceed those of non-lactating women. caution should be exercised when infuvite pediatric is administered to nursing mothers. infuvite pediatric is approved for the prevention of vitamin deficiency in pediatric patients up to 11 years

Canada - English - Health Canada

pharmaceutical partners of canada inc - zinc (zinc sulfate); copper (cupric sulfate); manganese (manganese sulfate); chromium (chromic chloride); selenium (selenious acid); iodide (sodium iodide) - solution - 5mg; 1mg; 0.5mg; 10mcg; 60mcg; 75mcg - zinc (zinc sulfate) 5mg; copper (cupric sulfate) 1mg; manganese (manganese sulfate) 0.5mg; chromium (chromic chloride) 10mcg; selenium (selenious acid) 60mcg; iodide (sodium iodide) 75mcg - replacement preparations

Canada - English - Health Canada

pharmaceutical partners of canada inc - zinc (zinc sulfate); copper (cupric sulfate); manganese (manganese sulfate); chromium (chromic chloride) - solution - 5mg; 1mg; 0.5mg; 10mcg - zinc (zinc sulfate) 5mg; copper (cupric sulfate) 1mg; manganese (manganese sulfate) 0.5mg; chromium (chromic chloride) 10mcg - replacement preparations

Canada - English - Health Canada

pharmaceutical partners of canada inc - zinc (zinc sulfate); copper (cupric sulfate); manganese (manganese sulfate); chromium (chromic chloride) - solution - 1mg; 0.4mg; 0.1mg; 4mcg - zinc (zinc sulfate) 1mg; copper (cupric sulfate) 0.4mg; manganese (manganese sulfate) 0.1mg; chromium (chromic chloride) 4mcg - replacement preparations

Israel - English - Ministry of Health

amgen europe b.v. - blinatumomab - powder for concentrate for solution for infusion - blinatumomab 35 mcg / 1 vial - blinatumomab - • blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b- precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options.• blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%.• blincyto is indicated as monotherapy for the treatment of pediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b-cell precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.• blincyto is indicated as monotherapy for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b precursor all as part of the consolidation therapy.limitations of use: after failure of two previous treatments and with no cns involvement.